Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about RHHVF
Recent news which mentions RHHVF
< Previous
1
2
3
4
5
Next >
FDA Approves Expanded Use Of Roche's Influenza Treatment
August 12, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
RHHVF
Market News
From
Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
August 08, 2022
Tickers
AMGN
MRK
RHHBF
RHHBY
Tags
RHHBY
Biotech
Benzinga
From
Benzinga
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field
August 03, 2022
Tickers
PSTX
RHHBF
RHHBY
RHHVF
Tags
PSTX
Trading Ideas
Briefs
From
Benzinga
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
July 25, 2022
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
REGN
Briefs
General
From
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Tickers
ABBV
ABUS
ASMB
HLVX
Tags
ZYNE
Offerings
HLVX
From
Benzinga
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
July 21, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
General
News
Briefs
From
Benzinga
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
July 18, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
News
General
Health Care
From
Benzinga
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
July 11, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
RHHVF
Market News
From
Benzinga
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
July 06, 2022
Tickers
RHHBF
RHHBY
RHHVF
SRPT
Tags
SRPT
RHHBF
Benzinga
From
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Tickers
AMTI
BIIB
ESALF
ESALY
Tags
IFRX
Market News
RHHVF
From
Benzinga
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
June 16, 2022
Tickers
ACIU
RHHBF
RHHBY
RHHVF
Tags
ACIU
RHHBF
Large Cap
From
Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
June 06, 2022
Tickers
BNTX
MRK
RHHBF
RHHBY
Tags
Large Cap
RHHBF
RHHBY
From
Benzinga
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
May 23, 2022
Tickers
MRK
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHVF
Health Care
From
Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
May 11, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
RHHVF
Market News
From
Benzinga
Roche Releases More Evrysdi Data For Very Young Infants With SMA
April 29, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
Biotech
RHHBY
From
Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
April 25, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
Biotech
RHHBY
From
Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
April 25, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Guidance
Earnings
RHHBF
From
Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
April 22, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
News
General
Health Care
From
Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
April 20, 2022
Tickers
A
ILMN
MYGN
NTRA
Tags
Benzinga
FDA
RHHBY
From
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
April 13, 2022
Tickers
PLRX
RHHBF
RHHBY
RHHVF
Tags
Analyst Ratings
Health Care
Movers
From
Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
April 04, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
Biotech
RHHBY
From
Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
April 04, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
News
General
Briefs
From
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
March 30, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Biotech
RHHBY
Benzinga
From
Benzinga
Drug makers, Scientists Working For Long COVID Treatments: Reuters
March 25, 2022
Tickers
AXLA
GSK
HGEN
MRNA
Tags
MRNA
PRTC
Penny Stocks
From
Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
Tickers
PTCT
RHHBF
RHHBY
RHHVF
Tags
Health Care
PTCT
Market News
From
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Tickers
BAYRY
BAYZF
EXEL
IPSEY
Tags
BAYRY
Liver Cancer
General
From
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Tickers
ANY
NVS
REGN
RHHBF
Tags
Market News
RHHVF
Health Care
From
Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
February 03, 2022
Tickers
NVS
RHHBF
RHHBY
RHHVF
Tags
General
News
Health Care
From
Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
Tickers
NVS
RHHBF
RHHBY
RHHVF
Tags
Briefs
General
News
From
Benzinga
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
February 01, 2022
Tickers
BIIB
RHHBF
RHHBY
RHHVF
Tags
Briefs
BIIB
Non Hodgkin Lymphoma
From
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.